Altimmune, Inc.
Every calculator, already run for ALT
Open the full toolkit →You have the numbers on ALT. Get the argument.
A written report on which of these readings actually decide the outcome for Altimmune, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering ALTAnalyst Price Target Disagreement for Altimmune, Inc.
Wall Street's bull case implies +852% from the current price; the bear case implies +274%. A 578% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
ALT — frequently asked
Is ALT a buy right now?
Wall Street's consensus rating on Altimmune, Inc. is Strong Buy across 10 analysts, with a mean price target of $17.22 (+486% vs. the current $2.94). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ALT's next earnings date?
Altimmune, Inc. is next scheduled to report earnings around Nov 5, 2026. A full ALT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Altimmune, Inc.?
Analysts covering Altimmune, Inc. (ALT) range from a bear-case target of $11.00 to a bull-case high of $28.00, with a mean consensus target of $17.22 across 9 analysts. The spread of $17.00 (578% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Altimmune, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Altimmune, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Altimmune, Inc., in minutes. 3 free reports included with every account — no credit card required.